Medical Device Stocks
Recent market-moving SEC filings and news across medical device companies, ranked by Wiseek's 1–10 importance score.
How Wiseek curates this list
Every item here is a high-importance (score ≥ 7) SEC filing or licensed news event for a medical device company, sourced from SEC EDGAR and licensed news wires and ranked by Wiseek's 1–10 importance score. The underlying source is linked from each article. See our methodology and editorial policy.
Related Healthcare industries
Biotech StocksPharmaceutical StocksHealth Tech StocksDiagnostics & Research StocksMedical Instrument StocksHealthcare Facility Stocks
See the full Healthcare sector feed.
iRadimed Launches New 3870 MR IV Pump, Guides Q3 Revenue Up 12-20%
Nexalin Secures $1M Note with Onerous Terms Amid Delisting Fight
Elutia Closes SimpliDerm Sale, Receives $7.7M Cash to Fund NXT-41x Launch
Aethlon Medical Seeks 10x Authorized Share Increase and Blank-Check Preferred Stock
Profusa Issues $714K Convertible Note and Exchanges $6.1M Debt for Preferred Stock
Streamex Reports First Revenue, $41.8M Liquidity, and GLDC Launch Plans
Nexalin Secures $15M Equity Line with Alumni Capital and Adds $750K Direct Offering
Nexalin Secures $750K Direct Offering and $15M Equity Facility to Fund Pivotal Trial
Viemed Reaffirms 2026 Guidance and Authorizes New 5% Buyback
Abbott Settles Key Preterm Infant Formula Lawsuits for $670 Million, Reducing Legal Overhang
Abbott Settles NEC Litigation for $670M, Resolving Gill Case and 2,000 Claims
Lifeward Appoints Three New Directors, Including New Board Chair, as Director Resigns
Profusa Advances G3 Vision Labs Acquisition with $10.7M Debt-to-Equity Exchanges and $650K Borrowing
Profusa Swings to $28.4M Equity After $8.8M Q2 Loss, G3 Deal Progresses
FDA Clears Hyperfine's Next Optive AI Software, Adding 3D Imaging to Portable MRI
Fortitude's Strong Q2 and $1M Stake in HeartSciences at a 22% Premium
Fortitude Buys $1M of HeartSciences Stock at 22% Premium, Reports Strong Q2 Mining Results
Fortitude Posts $20.9M Q2 Revenue, Buys 9.4% Stake in HeartSciences at 22% Premium
Activist 3i, LP Sells 2.8M Shares, Converts Preferred, and Injects $1.5M in Valion Bio
CFO Converts $1.29M Note into 301,991 Shares at $4.28
Insiders Convert $1.3M Debt to 49.9% Stake in Profusa
CEO Converts $1.29M Note into 301,991 Shares at $4.28 Post-Split
HeartSciences Files Fortitude Interim Financials Showing $14.2M Loss and $10.3M Impairment
HeartSciences Files Fortitude Interim Financials: $14.2M Loss, $10.3M Impairment, and Weather Damage
ADM Tronics Swings to Q1 Loss, Reaffirms Going Concern Warning
Fortitude's $1M Investment in HeartSciences at a 22% Premium Leaves Merger Terms Unchanged
Fortitude Invests $1.0M in HeartSciences at 22% Premium, No Change to Merger Terms
Envoy Medical Seeks Shareholder Approval for Reverse Stock Split to Regain Nasdaq Compliance
Profusa Q2 Loss Widens to $8.8M; Going Concern Doubts Persist Amid Reverse Splits and G3 Option
Biotricity Q1 FY2027: Revenue Climbs 10%, Yet Going Concern and Series C Exchange Loom
Accuray Q4 Revenue Plunges 21%, FY26 Loss Widens to $49M
Accuray Q4 Revenue Falls 21%, Withdraws FY27 Guidance Amid Recapitalization
Fortitude Invests $1M in HeartSciences at 22% Premium, Merger Terms Unchanged
Intelligent Bio Solutions Reports 38% Revenue Growth and 778bps Gross Margin Expansion
Intelligent Bio Solutions Posts 38% Revenue Growth on Cartridge Demand
INBS 10-K: Going Concern Warning, $12.4M Loss, but Revenue Up 38%
FDA Expands TearCare Label to Improve Meibomian Gland Function, a First for Dry Eye
Smith+Nephew CFO John Rogers Resigns; Interim CFO Named
Fortitude Buys 9.4% Stake in HeartSciences for $1M at Premium to Market
Profusa Seeks Blank-Check Reverse Split Authority to Avert Nasdaq Delisting